High Recurrence Score Linked with Chemotherapy Success in Breast Cancer
The results of the TAILORx trial went against previous ideas that breast cancer patients with a high Oncotype score who needed chemotherapy and endocrine therapy wouldn ' t fare well. (Source: CancerNetwork)
Source: CancerNetwork - October 8, 2019 Category: Cancer & Oncology Authors: Christina Bennett, MS Source Type: news
Genotyping for breast cancer endocrine therapy cost effective
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - September 30, 2019 Category: Drugs & Pharmacology Source Type: news
Now With Survival Benefit, CDK4/6 Inhibitors in Breast Cancer Now With Survival Benefit, CDK4/6 Inhibitors in Breast Cancer
New data for overall survival now establish adding the CDK4/6 inhibitors abemaciclib and ribociclib to endocrine therapy for frontline use in HR+/HER2- advanced breast cancer.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 30, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
New Support for Ovarian Suppression with Endocrine Therapy in Premenopausal Breast Cancer
A phase III study found that adding 2 years of ovarian function suppression to tamoxifen extended disease-free survival in certain patients with hormone receptor –positive breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - September 27, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news
Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update
Update of this US guidance now includes anastrazole as an option in postmenopausal women at increased risk. Tamoxifen 20 mg/day for 5yrs is still considered standard of care for risk reduction in premenopausal women who are at least 35 years old and have completed childbearing. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - September 5, 2019 Category: Consumer Health News Source Type: news
How Does Pharmacy Synchronization Help Endocrine Therapy Adherence?
Could something as simple as synchronizing medicine refills at the pharmacy help improve survival in patients with breast cancer using endocrine therapy? (Source: CancerNetwork)
Source: CancerNetwork - August 28, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news
Can PI3K Inhibitors Reduce Endocrine Therapy Resistance in Early Breast Cancer?
The new phase II LORELEI trial tested whether the PI3K inhibitor taselisib could improve response rates when added to letrozole in the neoadjuvant setting. (Source: CancerNetwork)
Source: CancerNetwork - August 28, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news
Extending Adjuvant Endocrine Therapy in Breast Cancer: Who, What, Why?
In this article, we provide a case-based expert opinion on the duration of extended adjuvant endocrine therapy, use of biomarkers in guiding this decision, and toxicities to be considered when recommending this treatment. (Source: CancerNetwork)
Source: CancerNetwork - June 19, 2019 Category: Cancer & Oncology Authors: Shaveta Vinayak, MD, MS, Nancy E. Davidson, MD Source Type: news
Endocrine Therapy Nonadherence and Discontinuation in Women Endocrine Therapy Nonadherence and Discontinuation in Women
What factors contribute to higher nonadherence rates reported in black women with hormone positive breast cancer?Journal of the National Cancer Institute (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 14, 2019 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
Premenopausal Women With Breast Cancer; New TAILORx Data Premenopausal Women With Breast Cancer; New TAILORx Data
An analysis of TAILORx showed that adding clinical risk refines its genomic risk model and may now identify a group of premenopausal women who may benefit from chemotherapy added to endocrine therapy.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 12, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Palbociclib and Endocrine Therapy for Advanced Breast Cancer Palbociclib and Endocrine Therapy for Advanced Breast Cancer
An analysis of longer-term PALOMA safety data finds that palbociclib plus endocrine therapy is not associated with specific cumulative or delayed toxicities.Journal of the National Cancer Institute (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - June 7, 2019 Category: Allergy & Immunology Tags: Hematology-Oncology Journal Article Source Type: news
ASCO: Survival Up With Ribociclib in Advanced Breast Cancer
TUESDAY, June 4, 2019 -- For premenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer, adding ribociclib to standard-of-care endocrine therapy is associated with improved overall... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 4, 2019 Category: Pharmaceuticals Source Type: news
Novartis Kisqali significantly extends life in women with HR+/HER2- advanced breast cancer in MONALEESA-7 trial
Novartis announced statistically significant overall survival (OS) results for Kisqali in combination with endocrine therapy[1]. The Phase 3 MONALEESA-7 trial evaluated Kisqali plus endocrine therapy (goserelin plus either an aromatase inhibitor or tamoxifen) as initial treatment compared to endocrine therapy alone in pre- and perimenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer[1]. (Source: World Pharma News)
Source: World Pharma News - June 3, 2019 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news
First CDK4/6 Inhibitor to Improve Survival in Metastatic Breast Cancer First CDK4/6 Inhibitor to Improve Survival in Metastatic Breast Cancer
Ribociclib plus standard-of-care endocrine therapy significantly improved overall survival for younger women with advanced hormone receptor-positive breast cancer vs endocrine therapy alone.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - June 2, 2019 Category: Drugs & Pharmacology Tags: Hematology-Oncology News Source Type: news
Adding ribociclib to hormone therapy extends lives of women with most common breast cancer
A UCLA-led study has found that using a drug called ribociclib in combination with a common hormone therapy may help premenopausal women with the most common type of breast cancer live longer than if they only receive the hormone therapy.Ribociclib is considered a cyclin-dependent kinase inhibitor that works by blocking the activity of proteins called cyclin-dependent kinase 4/6 enzymes, which promote cell division and cancer growth.The study involved 672 women aged 25 to 59 when the study began who had advanced hormone-receptor positive/HER2- breast cancer. Seventy percent of the women who took the combination therapy wer...
Source: UCLA Newsroom: Health Sciences - June 1, 2019 Category: Universities & Medical Training Source Type: news
